Table 4 Cost-utility results in scenario analyses
Intervention | Cost (USD) | Incremental Cost (USD) | QALYs | Incremental QALYs | ICER (USD/QALY) | |
|---|---|---|---|---|---|---|
Discount rate of 0% | Add-on dupilumab to background therapy | 154,798 | 118,232 | 11.24 | 6.46 | 18,303 |
Background therapy alone | 36,566 | 4.78 | ||||
Discount rate of 3% | Add-on dupilumab to background therapy | 124,017 | 92,487 | 8.88 | 4.71 | 19,640 |
Background therapy alone | 31,530 | 4.17 | ||||
Time horizon 10 years | Add-on dupilumab to background therapy | 86,595 | 60,554 | 5.97 | 2.46 | 24,625 |
Background therapy alone | 26,041 | 3.51 | ||||
Time horizon 20 years | Add-on dupilumab to background therapy | 107,913 | 78,715 | 7.65 | 3.76 | 20,935 |
Background therapy alone | 29,198 | 3.89 | ||||
Long-term risk of experiencing severe exacerbations based on observed trial data without adjustment | Add-on dupilumab to background therapy | 112,040 | 83,664 | 9.08 | 3.74 | 22,386 |
Background therapy alone | 28,376 | 5.35 | ||||
Fatality rate for exacerbation requiring office or ED visit: assumed to be equal to all-cause mortality of the general population | Add-on dupilumab to background therapy | 126,864 | 74,533 | 9.60 | 2.98 | 24,999 |
Background therapy alone | 52,332 | 6.62 | ||||
Utility weights: applied based on published literature | Add-on dupilumab to background therapy | 112,924 | 83,379 | 7.94 | 4.24 | 19,674 |
Background therapy alone | 29,545 | 3.71 | ||||
Includes the productivity loss costs from a societal perspective | Add-on dupilumab to background therapy | 119,240 | 72,845 | 8.03 | 4.10 | 17,757 |
Background therapy alone | 46,396 | 3.93 |